Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
ProQuad + Infanrix hexa refers to the concomitant administration of two separate vaccines: ProQuad (a live attenuated measles, mumps, rubella, and varicella vaccine) and Infanrix hexa (a hexavalent vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens, recombinant hepatitis B surface antigen, inactivated poliovirus, and Haemophilus influenzae type b conjugate). This combination is typically studied as a booster regimen in children aged 12 to 23 months to provide simultaneous protection against ten infectious diseases. Clinical data indicates that the co-administration is safe and immunogenic, with no significant interference between the various antigenic components.
- Other names
- MMRV + DTaP-HepB-IPV-Hib
02
Targets
BCR (Immunoglobulin G B Cell Receptor)SLAMF1 (SLAM family member 1)CD46 (CD46 Molecule)IDE (Insulin-degrading enzyme)PRR (Pattern recognition receptors)γδ TCR (T-cell receptor)FHA (Filamentous hemagglutinin)PRNP (Cellular Prion Protein)HBsAg (Hepatitis B surface antigen)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles, mumps, rubella, and varicella vaccine + diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and haemophilus influenzae type b vaccine.